# A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

> **NCT04503265** · PHASE1,PHASE2 · RECRUITING · sponsor: **AtlasMedx, Incorporated** · enrollment: 122 (estimated)

## Conditions studied

- Advanced Malignant Neoplasm
- Breast Cancer
- Ovarian Cancer
- Homologous Recombination Deficiency
- Prostate Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** AMXI-5001:Dose Escalation Phase I
- **DRUG:** AMXI-5001:Dose Expansion Phase II

## Key facts

- **NCT ID:** NCT04503265
- **Lead sponsor:** AtlasMedx, Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-12
- **Primary completion:** 2026-08
- **Final completion:** 2026-10
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2025-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503265, "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04503265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*